Home » Topics » Disease categories and therapies » Endocrine/metabolic

Endocrine/metabolic
RSS

JT and Tularik to develop new antidiabetic agents

Oct. 18, 1996

Novo Nordisk enters collaboration on PTPase inhibitors

Oct. 18, 1996

U.S. patent covers Celtrix's SomatoKine

Oct. 18, 1996

New NPY antagonists from Warner-Lambert

Oct. 18, 1996

Warner-Lambert describes NK2 antagonists for obesity

Oct. 18, 1996

Antiobesity proteins described by Lilly

Oct. 18, 1996

Anorexigenic dihydropyridine compounds from Bristol-Myers Squibb

Oct. 18, 1996

Lilly claims compounds for women's health

Oct. 18, 1996

Atosiban efficacy in treating preterm labor

Oct. 11, 1996

Yamanouchi awaits marketing approval for new contraceptive

Oct. 11, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 18, 2025.
European VCs optimistic for med-tech exit opportunities in 2025
BioWorld MedTech
To say that European investors are optimistic about the outlook for the med-tech sector in 2025 is an understatement. A couple of companies are already listed on...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Feb. 14, 2025
European VCs bullish on med-tech investments in 2025
BioWorld MedTech
European companies looking for capital should find the fundraising environment more favorable in 2025. Private med-tech financings in January totaled about $2...
Kura/Kyowa Kirin’s ziftomenib hits phase II endpoints in AML
BioWorld
Kura Oncology Inc. and Kyowa Kirin Co. Ltd.’s selective oral menin inhibitor, ziftomenib, met the primary endpoints in the phase II registrational Komet-001 trial...